Marksans Pharma Limited

NSEI:MARKSANS 주식 보고서

시가총액: ₹136.0b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Marksans Pharma 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Mark Saldanha

최고 경영자

₹68.9m

총 보상

CEO 급여 비율69.7%
CEO 임기9yrs
CEO 소유권43.8%
경영진 평균 재임 기간12.9yrs
이사회 평균 재임 기간6.2yrs

최근 관리 업데이트

Recent updates

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Sep 21
Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Jul 28
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Feb 16
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Jan 26
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Dec 02
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Jun 21
Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Nov 17
Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Sep 16
This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Sep 01
Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Jun 14
Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

May 27
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Feb 19
Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 04
Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Jan 20
Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Jan 05
Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%

Dec 21
Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%

What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?

Dec 06
What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?

These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely

Nov 19
These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely

CEO 보상 분석

Mark Saldanha 의 보수는 Marksans Pharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

₹3b

Mar 31 2024₹69m₹48m

₹3b

Dec 31 2023n/an/a

₹3b

Sep 30 2023n/an/a

₹3b

Jun 30 2023n/an/a

₹3b

Mar 31 2023₹52m₹48m

₹3b

Dec 31 2022n/an/a

₹2b

Sep 30 2022n/an/a

₹2b

Jun 30 2022n/an/a

₹2b

Mar 31 2022₹38m₹35m

₹2b

Dec 31 2021n/an/a

₹2b

Sep 30 2021n/an/a

₹2b

Jun 30 2021n/an/a

₹3b

Mar 31 2021₹10m₹10m

₹2b

Dec 31 2020n/an/a

₹2b

Sep 30 2020n/an/a

₹2b

Jun 30 2020n/an/a

₹1b

Mar 31 2020₹10m₹10m

₹1b

Dec 31 2019n/an/a

₹879m

Sep 30 2019n/an/a

₹834m

Jun 30 2019n/an/a

₹780m

Mar 31 2019₹10m₹10m

₹804m

Dec 31 2018n/an/a

₹666m

Sep 30 2018n/an/a

₹582m

Jun 30 2018n/an/a

₹463m

Mar 31 2018₹12m₹10m

₹358m

보상 대 시장: Mark 의 총 보상 ($USD 820.16K )은 Indian 시장( $USD 474.17K ).

보상과 수익: Mark 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Mark Saldanha (52 yo)

9yrs

테뉴어

₹68,857,053

보상

Mr. Mark B. Saldanha, M.Sc. (Maths) & (Stat.)., Dip. (Fin. Mgt.) serves as Promoter and Managing Director of Marksans Pharma Limited, which he joined in October 6, 2005 (alternate name, Glenmark Laboratori...

리더십 팀

이름위치테뉴어보상소유권
Mark Saldanha
Non-Independent Executive Chairman & MDno data₹68.86m43.8%
₹ 59.6b
Jitendra Sharma
Chief Financial Officer22.1yrs₹12.84m데이터 없음
Harshavardhan Panigrahi
Company Secretary15.7yrs₹2.84m데이터 없음
Sandra Saldanha
Whole-Time Executive Non Independent Director10.1yrs₹7.07m0.073%
₹ 99.2m
Varddhman Jain
Whole-Time Executive Non Independent Director5.8yrs₹18.75m데이터 없음
Sunil Rane
Senior Vice President of QCno data₹10.61m데이터 없음
Vishal Bhargava
Director Operationsno data데이터 없음데이터 없음
David Mohammed
Managing Director of Australia Operationsno data데이터 없음데이터 없음
Sathish Kumar
Managing Director of UK Operationsno data데이터 없음데이터 없음
Anjani Kumar
Chief Operating Officer of US Operationsno data₹10.29m데이터 없음

12.9yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: MARKSANS 의 관리팀은 노련하고 경험 (평균 재직 기간 12.8 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Mark Saldanha
Non-Independent Executive Chairman & MD9yrs₹68.86m43.8%
₹ 59.6b
Sandra Saldanha
Whole-Time Executive Non Independent Director10.1yrs₹7.07m0.073%
₹ 99.2m
Varddhman Jain
Whole-Time Executive Non Independent Director5.8yrs₹18.75m데이터 없음
Sunny Sharma
Non-Executive & Non-Independent Director3.2yrs데이터 없음데이터 없음
Abhinna Mohanty
Non-Executive & Independent Director5.3yrs₹15.00k데이터 없음
Shailaja Vardhan
Non-Executive & Independent Director1.4yrs₹300.00k데이터 없음
Seetharama Buddharaju
Non-Executive & Independent Director13yrs₹25.00k데이터 없음
Digant Parikh
Non-Executive Independent Director6.6yrs₹400.00k데이터 없음

6.2yrs

평균 재임 기간

53.5yo

평균 연령

경험이 풍부한 이사회: MARKSANS 의 이사회는 경험(평균 재직 기간 5.8 년)으로 간주됩니다.